HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use KOMBIGLYZE XR safely and effectively. See full prescribing information for KOMBIGLYZE XR.

KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) tablets Initial U.S. Approval: 2010

---

2 DOSAGE AND ADMINISTRATION

1 INDICATIONS AND USAGE

WARNING: LACTIC ACIDOSIS

See full prescribing information for complete boxed warning.

- Lactic acidosis can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure. (5.1)
- Symptoms include malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap, and elevated blood lactate. (5.1)
- If acidosis is suspected, discontinue KOMBIGLYZE XR and hospitalize the patient immediately. (5.1)

---

RECENT MAJOR CHANGES

Indications and Usage
Important Limitations of Use (1.1) 11/2011
Dosage and Administration
Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin (2.3) 03/2012
Contraindications (4) 11/2011
Warnings and Precautions
Pancreatitis (5.2) 11/2011
Use with Medications Known to Cause Hypoglycemia (5.9) 03/2012
Hypersensitivity Reactions (5.13) 11/2011

---

INDICATIONS AND USAGE

KOMBIGLYZE XR is a dipeptidyl peptidase-4 (DPP4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. (1, 14)

Important limitations of use:
- Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.1)
- Has not been studied in patients with a history of pancreatitis. (1.1, 5.2)

---

DOSEAGE AND ADMINISTRATION

- Administer once daily with the evening meal. (2.1)
- Individualize the starting dose based on the patient’s current regimen then adjust the dose based on effectiveness and tolerability. (2.1)
- Do not exceed a daily dose of 5 mg saxagliptin/2000 mg metformin HCl extended-release. (2.1)
- Swallow whole. Never crush, cut, or chew. (2.1)
- Limit the saxagliptin dose to 2.5 mg daily for patients also taking strong CYP3A4/5 inhibitors (e.g., ketoconazole). (2.2, 7.1)

---

DOSEAGE FORMS AND STRENGTHS

Tablets:
- 5 mg saxagliptin/500 mg metformin HCl extended-release (3)
- 5 mg saxagliptin/1000 mg metformin HCl extended-release (3)
- 2.5 mg saxagliptin/1000 mg metformin HCl extended-release (3)

---

CONTRAINDICATIONS

- Renal impairment. (4)
- Hypersensitivity to metformin hydrochloride. (4)
- Metabolic acidosis, including diabetic ketoacidosis. (4, 5.1)
- History of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to KOMBIGLYZE XR or saxagliptin. (4)

---

FULL PRESCRIBING INFORMATION: CONTENTS

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

2.2 Strong CYP3A4/5 Inhibitors

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Lactic Acidosis

5.2 Pancreatitis

5.3 Assessment of Renal Function

5.4 Impaired Hepatic Function

---

WARNINGS AND PRECAUTIONS

- Lactic acidosis: Warn patients against excessive alcohol intake. KOMBIGLYZE XR not recommended in hepatic impairment and contraindicated in renal impairment. Ensure normal renal function before initiating and at least annually thereafter. Temporarily discontinue KOMBIGLYZE XR in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. (4, 5.1, 5.3, 5.4, 5.7, 5.10, 5.11)
- There have been postmarketing reports of acute pancreatitis in patients taking saxagliptin. If pancreatitis is suspected, promptly discontinue KOMBIGLYZE XR. (5.2)
- Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. Measure hematological parameters annually. (5.5, 6.1)
- Hypoglycemia: When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia. (5.9)
- There have been postmarketing reports of serious hypersensitivity reactions, such as anaphylaxis, angioedema, and exfoliative skin conditions in patients treated with saxagliptin. In such cases, promptly discontinue KOMBIGLYZE XR, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. (5.13, 6.2)
- Macrovascular outcomes: No conclusive evidence of macrovascular risk reduction with KOMBIGLYZE XR or any other antidiabetic drug. (5.14)

---

ADVERSE REACTIONS

- Adverse reactions reported in >5% of patients treated with metformin extended-release and more commonly than in patients treated with placebo are: diarrhea and nausea/vomiting. (6.1)
- Adverse reactions reported in ≥5% of patients treated with saxagliptin and more commonly than in patients treated with placebo are: upper respiratory tract infection, urinary tract infection, and headache. (6.1)
- Adverse reactions reported in ≥5% of treatment-naive patients treated with coadministered saxagliptin and metformin and more commonly than in patients treated with metformin alone are: headache and nasopharyngitis.
- In the add-on to sulfonylurea and add-on to insulin trials, confirmed hypoglycemia was reported more commonly in patients treated with saxagliptin compared to placebo. (6.1)
- Hypersensitivity-related events (e.g., urticaria, facial edema) were reported more commonly in patients treated with saxagliptin than in patients treated with placebo. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

---

DRUG INTERACTIONS

- Coadministration with strong CYP3A4/5 inhibitors (e.g., ketoconazole) significantly increases saxagliptin concentrations. Limit KOMBIGLYZE XR dose to 2.5 mg/1000 mg once daily. (2.2, 7.1)
- Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination: use with caution. (5.10, 7.2)

---

USE IN SPECIFIC POPULATIONS

- No adequate and well-controlled studies in pregnant women. (8.1)
- Safety and effectiveness have not been established in children. (8.4)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide

Revised: 03/2012
5.5 Vitamin B12 Concentrations
5.6 Alcohol Intake
5.7 Surgical Procedures
5.8 Change in Clinical Status of Patients with Previously Controlled Type 2 Diabetes
5.9 Use with Medications Known to Cause Hypoglycemia
5.10 Concomitant Medications Affecting Renal Function or Metformin Disposition
5.11 Radiologic Studies with Intravascular Iodinated Contrast Materials
5.12 Hypoxic States
5.13 Hypersensitivity Reactions
5.14 Macrovascular Outcomes
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
  7.1 Strong Inhibitors of CYP3A4/5 Enzymes
  7.2 Cationic Drugs
  7.3 Use with Other Drugs
8 USE IN SPECIFIC POPULATIONS
  8.1 Pregnancy
  8.3 Nursing Mothers
  8.4 Pediatric Use
  8.5 Geriatric Use
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
  12.1 Mechanism of Action
  12.2 Pharmacodynamics
  12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
  13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
  13.2 Animal Toxicology
14 CLINICAL STUDIES
  14.1 Coadministration of Saxagliptin with Metformin Immediate-Release in Treatment-Naive Patients
  14.2 Addition of Saxagliptin to Metformin Immediate-Release
  14.3 Saxagliptin Add-On Combination Therapy with Metformin Immediate-Release versus Glipizide Add-On Combination Therapy with Metformin Immediate-Release
  14.4 Saxagliptin Add-On Combination Therapy with Insulin (with or without Metformin Immediate-Release)
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
  17.1 Instructions

* Sections or subsections omitted from the full prescribing information are not listed
FULL PRESCRIBING INFORMATION

WARNING: LACTIC ACIDOSIS

Lactic acidosis is a rare, but serious, complication that can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure.

The onset of lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress.

Laboratory abnormalities include low pH, increased anion gap, and elevated blood lactate.

If acidosis is suspected, KOMBIGLYZE XR should be discontinued and the patient hospitalized immediately. [See Warnings and Precautions (5.1).]

1 INDICATIONS AND USAGE

KOMBIGLYZE XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. [See Clinical Studies (14).]

1.1 Important Limitations of Use

KOMBIGLYZE XR should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

KOMBIGLYZE XR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using KOMBIGLYZE XR. [See Warnings and Precautions (5.2).]
2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

The dosage of KOMBIGLYZE XR should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability. KOMBIGLYZE XR should generally be administered once daily with the evening meal, with gradual dose titration to reduce the gastrointestinal side effects associated with metformin. The following dosage forms are available:

- KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) tablets 5 mg/500 mg
- KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) tablets 5 mg/1000 mg
- KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) tablets 2.5 mg/1000 mg

The recommended starting dose of KOMBIGLYZE XR in patients who need 5 mg of saxagliptin and who are not currently treated with metformin is 5 mg saxagliptin/500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

In patients treated with metformin, the dose of KOMBIGLYZE XR should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. Following a switch from metformin immediate-release to metformin extended-release, glycemic control should be closely monitored and dosage adjustments made accordingly.

Patients who need 2.5 mg saxagliptin in combination with metformin extended-release may be treated with KOMBIGLYZE XR 2.5 mg/1000 mg. Patients who need 2.5 mg saxagliptin who are either metformin naive or who require a dose of metformin higher than 1000 mg should use the individual components.

The maximum daily recommended dose is 5 mg for saxagliptin and 2000 mg for metformin extended-release.

No studies have been performed specifically examining the safety and efficacy of KOMBIGLYZE XR in patients previously treated with other antihyperglycemic medications and switched to KOMBIGLYZE XR. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.
Inform patients that KOMBIGLYZE XR tablets must be swallowed whole and never crushed, cut, or chewed. Occasionally, the inactive ingredients of KOMBIGLYZE XR will be eliminated in the feces as a soft, hydrated mass that may resemble the original tablet.

### 2.2 Strong CYP3A4/5 Inhibitors

The maximum recommended dose of saxagliptin is 2.5 mg once daily when coadministered with strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). For these patients, limit the KOMBIGLYZE XR dose to 2.5 mg/1000 mg once daily. [See Dosage and Administration (2.1), Drug Interactions (7.1), and Clinical Pharmacology (12.3).]

### 2.3 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin

When KOMBIGLYZE XR is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia. [See Warnings and Precautions (5.9).]

### 3 DOSAGE FORMS AND STRENGTHS

- KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) 5 mg/500 mg tablets are light brown to brown, biconvex, capsule-shaped, film-coated tablets with “5/500” printed on one side and “4221” printed on the reverse side, in blue ink.

- KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) 5 mg/1000 mg tablets are pink, biconvex, capsule-shaped, film-coated tablets with “5/1000” printed on one side and “4223” printed on the reverse side, in blue ink.

- KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) 2.5 mg/1000 mg tablets are pale yellow to light yellow, biconvex, capsule-shaped, film-coated tablets with “2.5/1000” printed on one side and “4222” printed on the reverse side, in blue ink.

### 4 CONTRAINDICATIONS

KOMBIGLYZE XR is contraindicated in patients with:
- Renal impairment (e.g., serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women, or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia.

- Hypersensitivity to metformin hydrochloride.

- Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin.

- History of a serious hypersensitivity reaction to KOMBIGLYZE XR or saxagliptin, such as anaphylaxis, angioedema, or exfoliative skin conditions. [See Warnings and Precautions (5.13) and Adverse Reactions (6.2).]

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Lactic Acidosis

Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with KOMBIGLYZE XR; when it occurs, it is fatal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic acidosis is characterized by elevated blood lactate levels (>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis, metformin plasma levels >5 µg/mL are generally found.

The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patient-years). In more than 20,000 patient-years exposure to metformin in clinical trials, there were no reports of lactic acidosis. Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient’s age. The risk of lactic acidosis may, therefore, be significantly decreased by regular monitoring of renal function.
in patients taking metformin and by use of the minimum effective dose of metformin. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Metformin treatment should not be initiated in patients ≥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. In addition, metformin should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clear lactate, metformin should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive alcohol intake when taking metformin since alcohol potentiates the effects of metformin hydrochloride on lactate metabolism. In addition, metformin should be temporarily discontinued prior to any intravascular radiographic study and for any surgical procedure [see Warnings and Precautions (5.3, 5.6, 5.7, 5.11)].

The onset of lactic acidosis often is subtle and accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, and resistant bradyarrhythmias with more marked acidosis. The patient and the patient’s physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur [see Warnings and Precautions (5.12)]. Metformin should be withdrawn until the situation is clarified. Serum electrolytes, ketones, blood glucose, and if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of metformin, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

Levels of fasting venous plasma lactate above the upper limit of normal, but less than 5 mmol/L, in patients taking metformin do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling. [See Warnings and Precautions (5.8).]

Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).

Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking metformin, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin hydrochloride is dialyzable
(with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery [see Contraindications (4) and Warnings and Precautions (5.6, 5.7, 5.10, 5.11, 5.12)].

### 5.2 Pancreatitis

There have been postmarketing reports of acute pancreatitis in patients taking saxagliptin. After initiation of KOMBIGLYZE XR, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, KOMBIGLYZE XR should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using KOMBIGLYZE XR.

### 5.3 Assessment of Renal Function

Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Therefore, KOMBIGLYZE XR is contraindicated in patients with renal impairment [see Contraindications (4)].

Before initiation of KOMBIGLYZE XR, and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal impairment is anticipated (e.g., elderly), renal function should be assessed more frequently and KOMBIGLYZE XR discontinued if evidence of renal impairment is present.

### 5.4 Impaired Hepatic Function

Metformin use in patients with impaired hepatic function has been associated with some cases of lactic acidosis. Therefore, KOMBIGLYZE XR is not recommended in patients with hepatic impairment.

### 5.5 Vitamin B₁₂ Concentrations

In controlled clinical trials of metformin of 29-week duration, a decrease to subnormal levels of previously normal serum vitamin B₁₂ levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B₁₂ absorption
from the B\textsubscript{12}-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or vitamin B\textsubscript{12} supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on KOMBIGLYZE XR and any apparent abnormalities should be appropriately investigated and managed [see Adverse Reactions (6.1)].

Certain individuals (those with inadequate vitamin B\textsubscript{12} or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B\textsubscript{12} levels. In these patients, routine serum vitamin B\textsubscript{12} measurements at 2- to 3-year intervals may be useful.

5.6 Alcohol Intake

Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving KOMBIGLYZE XR.

5.7 Surgical Procedures

Use of KOMBIGLYZE XR should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient’s oral intake has resumed and renal function has been evaluated as normal.

5.8 Change in Clinical Status of Patients with Previously Controlled Type 2 Diabetes

A patient with type 2 diabetes previously well controlled on KOMBIGLYZE XR who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, KOMBIGLYZE XR must be stopped immediately and other appropriate corrective measures initiated.
5.9 Use with Medications Known to Cause Hypoglycemia

Saxagliptin

When saxagliptin was used in combination with a sulfonylurea or with insulin, medications known to cause hypoglycemia, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. [See Adverse Reactions (6.1).] Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia when used in combination with KOMBIGLYZE XR. [See Dosage and Administration (2.3).]

Metformin hydrochloride

Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs.

5.10 Concomitant Medications Affecting Renal Function or Metformin Disposition

Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion [see Drug Interactions (7.2)], should be used with caution.

5.11 Radiologic Studies with Intravascular Iodinated Contrast Materials

Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin. Therefore, in patients in whom any such study is planned, KOMBIGLYZE XR should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal.
5.12  Hypoxic States

Cardiovascular collapse (shock), acute congestive heart failure, acute myocardial infarction, and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on KOMBIGLYZE XR therapy, the drug should be promptly discontinued.

5.13  Hypersensitivity Reactions

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with saxagliptin. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with saxagliptin, with some reports occurring after the first dose. If a serious hypersensitivity reaction is suspected, discontinue KOMBIGLYZE XR, assess for other potential causes for the event, and institute alternative treatment for diabetes. [See Adverse Reactions (6.2)].

Use caution in a patient with a history of angioedema to another dipeptidyl peptidase-4 (DPP4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with KOMBIGLYZE XR.

5.14  Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with KOMBIGLYZE XR or any other antidiabetic drug.

6  ADVERSE REACTIONS

6.1  Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Monotherapy and Add-On Combination Therapy

Metformin hydrochloride

In placebo-controlled monotherapy trials of metformin extended-release, diarrhea and nausea/vomiting were reported in >5% of metformin-treated patients and more commonly than in placebo-treated patients (9.6% versus 2.6% for diarrhea and 6.5% versus 1.5% for nausea/vomiting). Diarrhea led to discontinuation of study medication in 0.6% of the patients treated with metformin extended-release.

Saxagliptin

In two placebo-controlled monotherapy trials of 24-week duration, patients were treated with saxagliptin 2.5 mg daily, saxagliptin 5 mg daily, and placebo. Three 24-week, placebo-controlled, add-on combination therapy trials were also conducted: one with metformin immediate-release, one with a thiazolidinedione (pioglitazone or rosiglitazone), and one with glyburide. In these three trials, patients were randomized to add-on therapy with saxagliptin 2.5 mg daily, saxagliptin 5 mg daily, or placebo. A saxagliptin 10 mg treatment arm was included in one of the monotherapy trials and in the add-on combination trial with metformin immediate-release.

In a prespecified pooled analysis of the 24-week data (regardless of glycemic rescue) from the two monotherapy trials, the add-on to metformin immediate-release trial, the add-on to thiazolidinedione (TZD) trial, and the add-on to glyburide trial, the overall incidence of adverse events in patients treated with saxagliptin 2.5 mg and saxagliptin 5 mg was similar to placebo (72.0% and 72.2% versus 70.6%, respectively). Discontinuation of therapy due to adverse events occurred in 2.2%, 3.3%, and 1.8% of patients receiving saxagliptin 2.5 mg, saxagliptin 5 mg, and placebo, respectively. The most common adverse events (reported in at least 2 patients treated with saxagliptin 2.5 mg or at least 2 patients treated with saxagliptin 5 mg) associated with premature discontinuation of therapy included lymphopenia (0.1% and 0.5% versus 0%, respectively), rash (0.2% and 0.3% versus 0.3%), blood creatinine increased (0.3% and 0% versus 0%), and blood creatine phosphokinase increased (0.1% and 0.2% versus 0%). The adverse reactions in this pooled analysis reported (regardless of investigator assessment of causality) in ≥5% of patients treated with saxagliptin 5 mg, and more commonly than in patients treated with placebo are shown in Table 1.
### Table 1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥5% of Patients Treated with Saxagliptin 5 mg and More Commonly than in Patients Treated with Placebo

<table>
<thead>
<tr>
<th>Condition</th>
<th>Saxagliptin 5 mg N=882 (%)</th>
<th>Placebo N=799 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper respiratory tract infection</td>
<td>68 (7.7)</td>
<td>61 (7.6)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>60 (6.8)</td>
<td>49 (6.1)</td>
</tr>
<tr>
<td>Headache</td>
<td>57 (6.5)</td>
<td>47 (5.9)</td>
</tr>
</tbody>
</table>

* The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue.

In patients treated with saxagliptin 2.5 mg, headache (6.5%) was the only adverse reaction reported at a rate ≥5% and more commonly than in patients treated with placebo.

In this pooled analysis, adverse reactions that were reported in ≥2% of patients treated with saxagliptin 2.5 mg or saxagliptin 5 mg and ≥1% more frequently compared to placebo included: sinusitis (2.9% and 2.6% versus 1.6%, respectively), abdominal pain (2.4% and 1.7% versus 0.5%), gastroenteritis (1.9% and 2.3% versus 0.9%), and vomiting (2.2% and 2.3% versus 1.3%).

The incidence rate of fractures was 1.0 and 0.6 per 100 patient-years, respectively, for saxagliptin (pooled analysis of 2.5 mg, 5 mg, and 10 mg) and placebo. The incidence rate of fracture events in patients who received saxagliptin did not increase over time. Causality has not been established and nonclinical studies have not demonstrated adverse effects of saxagliptin on bone.

An event of thrombocytopenia, consistent with a diagnosis of idiopathic thrombocytopenic purpura, was observed in the clinical program. The relationship of this event to saxagliptin is not known.

**Use in Combination with Insulin**

In the add-on to insulin trial [see Clinical Studies (14.4)], the incidence of adverse events, including serious adverse events and discontinuations due to adverse events, was similar between saxagliptin and placebo, except for confirmed hypoglycemia (see Hypoglycemia subsection).
Adverse Reactions Associated with Saxagliptin Coadministered with Metformin Immediate-Release in Treatment-Naive Patients with Type 2 Diabetes

Table 2 shows the adverse reactions reported (regardless of investigator assessment of causality) in ≥5% of patients participating in an additional 24-week, active-controlled trial of coadministered saxagliptin and metformin in treatment-naive patients.

Table 2: Coadministration of Saxagliptin and Metformin Immediate-Release in Treatment-Naive Patients: Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in ≥5% of Patients Treated with Combination Therapy of Saxagliptin 5 mg Plus Metformin Immediate-Release (and More Commonly than in Patients Treated with Metformin Immediate-Release Alone)

<table>
<thead>
<tr>
<th></th>
<th>Saxagliptin 5 mg + Metformin* N=320</th>
<th>Placebo + Metformin* N=328</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>24 (7.5)</td>
<td>17 (5.2)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>22 (6.9)</td>
<td>13 (4.0)</td>
</tr>
</tbody>
</table>

* Metformin immediate-release was initiated at a starting dose of 500 mg daily and titrated up to a maximum of 2000 mg daily.

In patients treated with the combination of saxagliptin and metformin immediate-release, either as saxagliptin add-on to metformin immediate-release therapy or as coadministration in treatment-naive patients, diarrhea was the only gastrointestinal-related event that occurred with an incidence ≥5% in any treatment group in both studies. In the saxagliptin add-on to metformin immediate-release trial, the incidence of diarrhea was 9.9%, 5.8%, and 11.2% in the saxagliptin 2.5 mg, 5 mg, and placebo groups, respectively. When saxagliptin and metformin immediate-release were coadministered in treatment-naive patients, the incidence of diarrhea was 6.9% in the saxagliptin 5 mg + metformin immediate-release group and 7.3% in the placebo + metformin immediate-release group.

**Hypoglycemia**

In the saxagliptin clinical trials, adverse reactions of hypoglycemia were based on all reports of hypoglycemia. A concurrent glucose measurement was not required or was normal in some patients. Therefore, it is not possible to conclusively determine that all these reports reflect true hypoglycemia.
The incidence of reported hypoglycemia for saxagliptin 2.5 mg and saxagliptin 5 mg versus placebo given as monotherapy was 4.0% and 5.6% versus 4.1%, respectively. In the add-on to metformin immediate-release trial, the incidence of reported hypoglycemia was 7.8% with saxagliptin 2.5 mg, 5.8% with saxagliptin 5 mg, and 5.0% with placebo. When saxagliptin and metformin immediate-release were coadministered in treatment-naive patients, the incidence of reported hypoglycemia was 3.4% in patients given saxagliptin 5 mg + metformin immediate-release and 4.0% in patients given placebo + metformin immediate-release.

In the active-controlled trial comparing add-on therapy with saxagliptin 5 mg to glipizide in patients inadequately controlled on metformin alone, the incidence of reported hypoglycemia was 3% (19 events in 13 patients) with saxagliptin 5 mg versus 36.3% (750 events in 156 patients) with glipizide. Confirmed symptomatic hypoglycemia (accompanying fingerstick blood glucose ≤50 mg/dL) was reported in none of the saxagliptin-treated patients and in 35 glipizide-treated patients (8.1%) (p<0.0001).

In the add-on to insulin trial, the overall incidence of reported hypoglycemia was 18.4% for saxagliptin 5 mg and 19.9% for placebo. However, the incidence of confirmed symptomatic hypoglycemia (accompanying fingerstick blood glucose ≤50 mg/dL) was higher with saxagliptin 5 mg (5.3%) versus placebo (3.3%). Among the patients using insulin in combination with metformin, the incidence of confirmed symptomatic hypoglycemia was 4.8% with saxagliptin versus 1.9% with placebo [see Warnings and Precautions (5.9)].

**Hypersensitivity Reactions**

**Saxagliptin**

Hypersensitivity-related events, such as urticaria and facial edema in the 5-study pooled analysis up to Week 24 were reported in 1.5%, 1.5%, and 0.4% of patients who received saxagliptin 2.5 mg, saxagliptin 5 mg, and placebo, respectively. None of these events in patients who received saxagliptin required hospitalization or were reported as life-threatening by the investigators. One saxagliptin-treated patient in this pooled analysis discontinued due to generalized urticaria and facial edema.
**Infections**

*Saxagliptin*

In the unblinded, controlled, clinical trial database for saxagliptin to date, there have been 6 (0.12%) reports of tuberculosis among the 4959 saxagliptin-treated patients (1.1 per 1000 patient-years) compared to no reports of tuberculosis among the 2868 comparator-treated patients. Two of these six cases were confirmed with laboratory testing. The remaining cases had limited information or had presumptive diagnoses of tuberculosis. None of the six cases occurred in the United States or in Western Europe. One case occurred in Canada in a patient originally from Indonesia who had recently visited Indonesia. The duration of treatment with saxagliptin until report of tuberculosis ranged from 144 to 929 days. Post-treatment lymphocyte counts were consistently within the reference range for four cases. One patient had lymphopenia prior to initiation of saxagliptin that remained stable throughout saxagliptin treatment. The final patient had an isolated lymphocyte count below normal approximately four months prior to the report of tuberculosis. There have been no spontaneous reports of tuberculosis associated with saxagliptin use. Causality has not been established and there are too few cases to date to determine whether tuberculosis is related to saxagliptin use.

There has been one case of a potential opportunistic infection in the unblinded, controlled clinical trial database to date in a saxagliptin-treated patient who developed suspected foodborne fatal salmonella sepsis after approximately 600 days of saxagliptin therapy. There have been no spontaneous reports of opportunistic infections associated with saxagliptin use.

**Vital Signs**

*Saxagliptin*

No clinically meaningful changes in vital signs have been observed in patients treated with saxagliptin alone or in combination with metformin.
**Laboratory Tests**

**Absolute Lymphocyte Counts**

*Saxagliptin*

There was a dose-related mean decrease in absolute lymphocyte count observed with saxagliptin. From a baseline mean absolute lymphocyte count of approximately 2200 cells/microL, mean decreases of approximately 100 and 120 cells/microL with saxagliptin 5 mg and 10 mg, respectively, relative to placebo were observed at 24 weeks in a pooled analysis of five placebo-controlled clinical studies. Similar effects were observed when saxagliptin 5 mg and metformin were coadministered in treatment-naive patients compared to placebo and metformin. There was no difference observed for saxagliptin 2.5 mg relative to placebo. The proportion of patients who were reported to have a lymphocyte count \( \leq 750 \) cells/microL was 0.5%, 1.5%, 1.4%, and 0.4% in the saxagliptin 2.5 mg, 5 mg, 10 mg, and placebo groups, respectively. In most patients, recurrence was not observed with repeated exposure to saxagliptin although some patients had recurrent decreases upon rechallenge that led to discontinuation of saxagliptin. The decreases in lymphocyte count were not associated with clinically relevant adverse reactions.

The clinical significance of this decrease in lymphocyte count relative to placebo is not known. When clinically indicated, such as in settings of unusual or prolonged infection, lymphocyte count should be measured. The effect of saxagliptin on lymphocyte counts in patients with lymphocyte abnormalities (e.g., human immunodeficiency virus) is unknown.

**Platelets**

*Saxagliptin*

Saxagliptin did not demonstrate a clinically meaningful or consistent effect on platelet count in the six, double-blind, controlled clinical safety and efficacy trials.

**Vitamin B\textsubscript{12} Concentrations**

*Metformin hydrochloride*

Metformin may lower serum vitamin B\textsubscript{12} concentrations. Measurement of hematologic parameters on an annual basis is advised in patients on KOMBIGLYZE XR and any apparent
abnormalities should be appropriately investigated and managed. [See Warnings and Precautions (5.5).]

6.2 Postmarketing Experience

Additional adverse reactions have been identified during postapproval use of saxagliptin. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions. [See Contraindications (4) and Warnings and Precautions (5.13).]
- Acute pancreatitis. [See Indications and Usage (1.1) and Warnings and Precautions (5.2).]

7 DRUG INTERACTIONS

7.1 Strong Inhibitors of CYP3A4/5 Enzymes

**Saxagliptin**

Ketoconazole significantly increased saxagliptin exposure. Similar significant increases in plasma concentrations of saxagliptin are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). The dose of saxagliptin should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor. [See Dosage and Administration (2.2) and Clinical Pharmacology (12.3).]

7.2 Cationic Drugs

**Metformin hydrochloride**

Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in healthy volunteers. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of KOMBIGLYZE XR and/or the
interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.

7.3 Use with Other Drugs

*Metformin hydrochloride*

Some medications can predispose to hyperglycemia and may lead to loss of glycemic control. These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. When such drugs are administered to a patient receiving KOMBIGLYZE XR, the patient should be closely observed for loss of glycemic control. When such drugs are withdrawn from a patient receiving KOMBIGLYZE XR, the patient should be observed closely for hypoglycemia.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

*Pregnancy Category B*

There are no adequate and well-controlled studies in pregnant women with KOMBIGLYZE XR or its individual components. Because animal reproduction studies are not always predictive of human response, KOMBIGLYZE XR, like other antidiabetic medications, should be used during pregnancy only if clearly needed.

Coadministration of saxagliptin and metformin, to pregnant rats and rabbits during the period of organogenesis, was neither embryolethal nor teratogenic in either species when tested at doses yielding systemic exposures (AUC) up to 100 and 10 times the maximum recommended human doses (MRHD; saxagliptin 5 mg and metformin 2000 mg), respectively, in rats; and 249 and 1.1 times the MRHDs in rabbits. In rats, minor developmental toxicity was limited to an increased incidence of wavy ribs; associated maternal toxicity was limited to weight decrements of 11% to 17% over the course of the study, and related reductions in maternal food consumption. In rabbits, coadministration was poorly tolerated in a subset of mothers (12 of 30), resulting in death, moribundity, or abortion. However, among surviving mothers with evaluable litters, maternal toxicity was limited to marginal reductions in body weight over the course of gestation.
days 21 to 29; and associated developmental toxicity in these litters was limited to fetal body weight decrements of 7%, and a low incidence of delayed ossification of the fetal hyoid.

*Saxagliptin*

Saxagliptin was not teratogenic at any dose tested when administered to pregnant rats and rabbits during periods of organogenesis. Incomplete ossification of the pelvis, a form of developmental delay, occurred in rats at a dose of 240 mg/kg, or approximately 1503 and 66 times human exposure to saxagliptin and the active metabolite, respectively, at the MRHD of 5 mg. Maternal toxicity and reduced fetal body weights were observed at 7986 and 328 times the human exposure at the MRHD for saxagliptin and the active metabolite, respectively. Minor skeletal variations in rabbits occurred at a maternally toxic dose of 200 mg/kg, or approximately 1432 and 992 times the MRHD.

Saxagliptin administered to female rats from gestation day 6 to lactation day 20 resulted in decreased body weights in male and female offspring only at maternally toxic doses (exposures \( \geq 1629 \) and 53 times saxagliptin and its active metabolite at the MRHD). No functional or behavioral toxicity was observed in offspring of rats administered saxagliptin at any dose.

Saxagliptin crosses the placenta into the fetus following dosing in pregnant rats.

*Metformin hydrochloride*

Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

### 8.3 Nursing Mothers

No studies in lactating animals have been conducted with the combined components of KOMBIGLYZE XR. In studies performed with the individual components, both saxagliptin and metformin are secreted in the milk of lactating rats. It is not known whether saxagliptin or metformin are secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when KOMBIGLYZE XR is administered to a nursing woman.
8.4 Pediatric Use

Safety and effectiveness of KOMBIGLYZE XR in pediatric patients have not been established.

8.5 Geriatric Use

KOMBIGLYZE XR

Elderly patients are more likely to have decreased renal function. Because metformin is contraindicated in patients with renal impairment, carefully monitor renal function in the elderly and use KOMBIGLYZE XR with caution as age increases. [See Warnings and Precautions (5.1, 5.3) and Clinical Pharmacology (12.3).]

Saxagliptin

In the six, double-blind, controlled clinical safety and efficacy trials of saxagliptin, 634 (15.3%) of the 4148 randomized patients were 65 years and over, and 59 (1.4%) patients were 75 years and over. No overall differences in safety or effectiveness were observed between patients ≥65 years old and the younger patients. While this clinical experience has not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out.

Metformin hydrochloride

Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and young patients. Metformin is known to be substantially excreted by the kidney. Because the risk of lactic acidosis with metformin is greater in patients with impaired renal function, KOMBIGLYZE XR should only be used in patients with normal renal function. The initial and maintenance dosing of metformin should be conservative in patients with advanced age due to the potential for decreased renal function in this population. Any dose adjustment should be based on a careful assessment of renal function. [See Contraindications (4), Warnings and Precautions (5.3), and Clinical Pharmacology (12.3).]
10 OVERDOSAGE

**Saxagliptin**

In a controlled clinical trial, once-daily, orally-administered saxagliptin in healthy subjects at doses up to 400 mg daily for 2 weeks (80 times the MRHD) had no dose-related clinical adverse reactions and no clinically meaningful effect on QTc interval or heart rate.

In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status. Saxagliptin and its active metabolite are removed by hemodialysis (23% of dose over 4 hours).

**Metformin hydrochloride**

Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see Warnings and Precautions (5.1)]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdose is suspected.

11 DESCRIPTION

KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) tablets contain two oral antihyperglycemic medications used in the management of type 2 diabetes: saxagliptin and metformin hydrochloride.

**Saxagliptin**

Saxagliptin is an orally-active inhibitor of the dipeptidyl-peptidase-4 (DPP4) enzyme.

Saxagliptin monohydrate is described chemically as \(\text{C}_{18}\text{H}_{25}\text{N}_{3}\text{O}_{2} \cdot \text{H}_{2}\text{O}\) and the molecular weight is 333.43. The structural formula is:
Saxagliptin monohydrate is a white to light yellow or light brown, non-hygroscopic, crystalline powder. It is sparingly soluble in water at 24°C ± 3°C, slightly soluble in ethyl acetate, and soluble in methanol, ethanol, isopropyl alcohol, acetonitrile, acetone, and polyethylene glycol 400 (PEG 400).

Metformin hydrochloride

Metformin hydrochloride (N,N-dimethylimidodicarbonimidic diamide hydrochloride) is a white to off-white crystalline compound with a molecular formula of C₄H₁₁N₅ • HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water, slightly soluble in alcohol, and is practically insoluble in acetone, ether, and chloroform. The pKₐ of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. The structural formula is:

KOMBIGLYZE XR

KOMBIGLYZE XR is available for oral administration as tablets containing either 5.58 mg saxagliptin hydrochloride (anhydrous) equivalent to 5 mg saxagliptin and 500 mg metformin hydrochloride (KOMBIGLYZE XR 5 mg/500 mg), or 5.58 mg saxagliptin hydrochloride (anhydrous) equivalent to 5 mg saxagliptin and 1000 mg metformin hydrochloride (KOMBIGLYZE XR 5 mg/1000 mg), or 2.79 mg saxagliptin hydrochloride (anhydrous) equivalent to 2.5 mg saxagliptin and 1000 mg metformin hydrochloride (KOMBIGLYZE XR 2.5 mg/1000 mg). Each film-coated tablet of KOMBIGLYZE XR contains the following inactive
ingredients: carboxymethylcellulose sodium, hypromellose 2208, and magnesium stearate. The 5 mg/500 mg strength tablet of KOMBIGLYZE XR also contains microcrystalline cellulose and hypromellose 2910. In addition, the film coatings contain the following inactive ingredients: polyvinyl alcohol, polyethylene glycol 3350, titanium dioxide, talc, and iron oxides.

The biologically inert components of the tablet may occasionally remain intact during gastrointestinal transit and will be eliminated in the feces as a soft, hydrated mass.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

KOMBIGLYZE XR

KOMBIGLYZE XR combines two antihyperglycemic medications with complementary mechanisms of action to improve glycemic control in adults with type 2 diabetes: saxagliptin, a dipeptidyl-peptidase-4 (DPP4) inhibitor, and metformin hydrochloride, a biguanide.

Saxagliptin

Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus.

Metformin hydrochloride

Metformin improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in patients with type 2 diabetes or in healthy subjects except in unusual circumstances [see
Warnings and Precautions (5.9)] and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

12.2 Pharmacodynamics

Saxagliptin

In patients with type 2 diabetes mellitus, administration of saxagliptin inhibits DPP4 enzyme activity for a 24-hour period. After an oral glucose load or a meal, this DPP4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased glucose-dependent insulin secretion from pancreatic beta cells. The rise in insulin and decrease in glucagon were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.

Cardiac Electrophysiology

Saxagliptin

In a randomized, double-blind, placebo-controlled, 4-way crossover, active comparator study using moxifloxacin in 40 healthy subjects, saxagliptin was not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 40 mg (8 times the MRHD).

12.3 Pharmacokinetics

KOMBIGLYZE XR

Bioequivalence and food effect of KOMBIGLYZE XR was characterized under low calorie diet. The low calorie diet consisted of 324 kcal with meal composition that contained 11.1% protein, 10.5% fat, and 78.4% carbohydrate. The results of bioequivalence studies in healthy subjects demonstrated that KOMBIGLYZE XR combination tablets are bioequivalent to coadministration of corresponding doses of saxagliptin (ONGLYZA®) and metformin hydrochloride extended-release (GLUCOPHAGE® XR) as individual tablets under fed conditions.
**Saxagliptin**

The pharmacokinetics of saxagliptin and its active metabolite, 5-hydroxy saxagliptin were similar in healthy subjects and in patients with type 2 diabetes mellitus. The $C_{\text{max}}$ and AUC values of saxagliptin and its active metabolite increased proportionally in the 2.5 to 400 mg dose range. Following a 5 mg single oral dose of saxagliptin to healthy subjects, the mean plasma AUC values for saxagliptin and its active metabolite were 78 ng•h/mL and 214 ng•h/mL, respectively. The corresponding plasma $C_{\text{max}}$ values were 24 ng/mL and 47 ng/mL, respectively. The average variability (%CV) for AUC and $C_{\text{max}}$ for both saxagliptin and its active metabolite was less than 25%.

No appreciable accumulation of either saxagliptin or its active metabolite was observed with repeated once-daily dosing at any dose level. No dose- and time-dependence were observed in the clearance of saxagliptin and its active metabolite over 14 days of once-daily dosing with saxagliptin at doses ranging from 2.5 to 400 mg.

**Metformin hydrochloride**

Metformin extended-release $C_{\text{max}}$ is achieved with a median value of 7 hours and a range of 4 to 8 hours. At steady state, the AUC and $C_{\text{max}}$ are less than dose proportional for metformin extended-release within the range of 500 to 2000 mg. After repeated administration of metformin extended-release, metformin did not accumulate in plasma. Metformin is excreted unchanged in the urine and does not undergo hepatic metabolism. Peak plasma levels of metformin extended-release tablets are approximately 20% lower compared to the same dose of metformin immediate-release tablets, however, the extent of absorption (as measured by AUC) is similar between extended-release tablets and immediate-release tablets.

**Absorption**

**Saxagliptin**

The median time to maximum concentration ($T_{\text{max}}$) following the 5 mg once daily dose was 2 hours for saxagliptin and 4 hours for its active metabolite. Administration with a high-fat meal resulted in an increase in $T_{\text{max}}$ of saxagliptin by approximately 20 minutes as compared to fasted conditions. There was a 27% increase in the AUC of saxagliptin when given with a meal as compared to fasted conditions. Saxagliptin may be administered with or without food. Food has
no significant effect on the pharmacokinetics of saxagliptin when administered as KOMBIGLYZE XR combination tablets.

*Metformin hydrochloride*

Following a single oral dose of metformin extended-release, $C_{max}$ is achieved with a median value of 7 hours and a range of 4 to 8 hours. Although the extent of metformin absorption (as measured by AUC) from the metformin extended-release tablet increased by approximately 50% when given with food, there was no effect of food on $C_{max}$ and $T_{max}$ of metformin. Both high and low fat meals had the same effect on the pharmacokinetics of metformin extended-release. Food has no significant effect on the pharmacokinetics of metformin when administered as KOMBIGLYZE XR combination tablets.

**Distribution**

*Saxagliptin*

The *in vitro* protein binding of saxagliptin and its active metabolite in human serum is negligible. Therefore, changes in blood protein levels in various disease states (e.g., renal or hepatic impairment) are not expected to alter the disposition of saxagliptin.

*Metformin hydrochloride*

Distribution studies with extended-release metformin have not been conducted; however, the apparent volume of distribution (V/F) of metformin following single oral doses of immediate-release metformin 850 mg averaged $654 \pm 358$ L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.

**Metabolism**

*Saxagliptin*

The metabolism of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). The major metabolite of saxagliptin is also a DPP4 inhibitor, which is one-half as potent as
saxagliptin. Therefore, strong CYP3A4/5 inhibitors and inducers will alter the pharmacokinetics of saxagliptin and its active metabolite. [See Drug Interactions (7.1).]

**Metformin hydrochloride**

Intravenous single-dose studies in healthy subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) or biliary excretion.

Metabolism studies with extended-release metformin tablets have not been conducted.

**Excretion**

**Saxagliptin**

Saxagliptin is eliminated by both renal and hepatic pathways. Following a single 50 mg dose of \(^{14}\)C-saxagliptin, 24%, 36%, and 75% of the dose was excreted in the urine as saxagliptin, its active metabolite, and total radioactivity, respectively. The average renal clearance of saxagliptin (~230 mL/min) was greater than the average estimated glomerular filtration rate (~120 mL/min), suggesting some active renal excretion. A total of 22% of the administered radioactivity was recovered in feces representing the fraction of the saxagliptin dose excreted in bile and/or unabsorbed drug from the gastrointestinal tract. Following a single oral dose of saxagliptin 5 mg to healthy subjects, the mean plasma terminal half-life (\(t_{1/2}\)) for saxagliptin and its active metabolite was 2.5 and 3.1 hours, respectively.

**Metformin hydrochloride**

Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.
Specific Populations

Renal Impairment

*KOMBIGLYZE XR*

In patients with decreased renal function (based on measured creatinine clearance), the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance. Use of metformin in patients with renal impairment increases the risk for lactic acidosis. Because KOMBIGLYZE XR contains metformin, KOMBIGLYZE XR is contraindicated in patients with renal impairment [see Contraindications (4) and Warnings and Precautions (5.3)].

Hepatic Impairment

No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment. Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Because KOMBIGLYZE XR contains metformin, KOMBIGLYZE XR is not recommended in patients with hepatic impairment [see Warnings and Precautions (5.4)].

Body Mass Index

*Saxagliptin*

No dosage adjustment is recommended based on body mass index (BMI) which was not identified as a significant covariate on the apparent clearance of saxagliptin or its active metabolite in the population pharmacokinetic analysis.

Gender

*Saxagliptin*

No dosage adjustment is recommended based on gender. There were no differences observed in saxagliptin pharmacokinetics between males and females. Compared to males, females had approximately 25% higher exposure values for the active metabolite than males, but this difference is unlikely to be of clinical relevance. Gender was not identified as a significant
covariate on the apparent clearance of saxagliptin and its active metabolite in the population pharmacokinetic analysis.

*Metformin hydrochloride*

Metformin pharmacokinetic parameters did not differ significantly between healthy subjects and patients with type 2 diabetes when analyzed according to gender (males=19, females=16). Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin was comparable in males and females.

*Geriatric*

*Saxagliptin*

No dosage adjustment is recommended based on age alone. Elderly subjects (65-80 years of age) had 23% and 59% higher geometric mean $C_{\text{max}}$ and geometric mean AUC values, respectively, for saxagliptin than young subjects (18-40 years of age). Differences in active metabolite pharmacokinetics between elderly and young subjects generally reflected the differences observed in saxagliptin pharmacokinetics. The difference between the pharmacokinetics of saxagliptin and the active metabolite in young and elderly subjects is likely due to multiple factors including declining renal function and metabolic capacity with increasing age. Age was not identified as a significant covariate on the apparent clearance of saxagliptin and its active metabolite in the population pharmacokinetic analysis.

*Metformin hydrochloride*

Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and $C_{\text{max}}$ is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.

KOMBIGLYZE XR should not be initiated in patients of any age unless measurement of creatinine clearance demonstrates that renal function is normal [see *Warnings and Precautions (5.1, 5.3)*].
**Pediatric**

Safety and effectiveness of KOMBIGLYZE XR in pediatric patients have not been established.

**Race and Ethnicity**

*Saxagliptin*

No dosage adjustment is recommended based on race. The population pharmacokinetic analysis compared the pharmacokinetics of saxagliptin and its active metabolite in 309 Caucasian subjects with 105 non-Caucasian subjects (consisting of six racial groups). No significant difference in the pharmacokinetics of saxagliptin and its active metabolite were detected between these two populations.

*Metformin hydrochloride*

No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n=249), blacks (n=51), and Hispanics (n=24).

**Drug Interactions**

Specific pharmacokinetic drug interaction studies with KOMBIGLYZE XR have not been performed, although such studies have been conducted with the individual saxagliptin and metformin components.

**In Vitro Assessment of Drug Interactions**

In *in vitro* studies, saxagliptin and its active metabolite did not inhibit CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4, or induce CYP1A2, 2B6, 2C9, or 3A4. Therefore, saxagliptin is not expected to alter the metabolic clearance of coadministered drugs that are metabolized by these enzymes. Saxagliptin is a P-glycoprotein (P-gp) substrate, but is not a significant inhibitor or inducer of P-gp.
# In Vivo Assessment of Drug Interactions

## Table 3: Effect of Coadministered Drug on Saxagliptin and 5-hydroxy Saxagliptin Systemic Exposures

| Coadministered Drug | Dose of Coadministered Drug* | Dosing of Saxagliptin* | Geometric Mean Ratio (ratio with/without coadministered drug) No Effect = 1.00 | | |
|---------------------|-----------------------------|------------------------|-----------------------------------------------------------------------------| | |
| No Effect = 1.00    | AUC† | Cmax | |
| No dosing adjustments required for the following: | | | |
| Metformin 1000 mg | 100 mg saxagliptin 5-hydroxy saxagliptin | 0.98 | 0.79 | 0.88 |
| Glyburide 5 mg | 10 mg saxagliptin 5-hydroxy saxagliptin | 0.98 ND | 1.08 ND | |
| Pioglitazone‡ 45 mg QD for 10 days | 10 mg QD for 5 days saxagliptin 5-hydroxy saxagliptin | 1.11 ND | 1.11 ND | |
| Digoxin 0.25 mg q6h first day followed by q12h second day followed by QD for 5 days | 10 mg QD for 7 days saxagliptin 5-hydroxy saxagliptin | 1.05 ND | 0.99 ND | 1.02 ND |
| Simvastatin 40 mg QD for 8 days | 10 mg QD for 4 days saxagliptin 5-hydroxy saxagliptin | 1.12 ND | 1.21 ND | 1.08 ND |
| Diltiazem 360 mg LA QD for 9 days | 10 mg saxagliptin 5-hydroxy saxagliptin | 2.09 ND | 1.63 ND | 0.57 ND |
| Rifampin§ 600 mg QD for 6 days | 5 mg saxagliptin 5-hydroxy saxagliptin | 0.24 ND | 0.47 ND | 1.39 ND |
| Omeprazole 40 mg QD for 5 days | 10 mg saxagliptin 5-hydroxy saxagliptin | 1.13 ND | 0.98 ND | 0.74 ND |
| Aluminum hydroxide + magnesium hydroxide + simethicone | aluminum hydroxide: 2400 mg magnesium hydroxide: 2400 mg simethicone: 240 mg | 10 mg saxagliptin 5-hydroxy saxagliptin | 0.97 ND | 0.74 ND | 0.74 ND |
| Famotidine 40 mg | 10 mg saxagliptin 5-hydroxy saxagliptin | 1.03 ND | 1.14 ND | |
Table 3: Effect of Coadministered Drug on Saxagliptin and 5-hydroxy Saxagliptin Systemic Exposures

<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>Dose of Coadministered Drug*</th>
<th>Dosing of Saxagliptin*</th>
<th>Geometric Mean Ratio (ratio with/without coadministered drug)</th>
<th>AUC†</th>
<th>Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>No Effect = 1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>200 mg BID for 9 days</td>
<td>100 mg</td>
<td>saxagliptin</td>
<td>2.45</td>
<td>0.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5-hydroxy saxagliptin</td>
<td>1.62</td>
<td>0.05</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>200 mg BID for 7 days</td>
<td>20 mg</td>
<td>saxagliptin</td>
<td>3.67</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5-hydroxy saxagliptin</td>
<td>2.44</td>
<td>ND</td>
</tr>
</tbody>
</table>

* Single dose unless otherwise noted.
† AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses
‡ Results exclude one subject.
§ The plasma dipeptidyl peptidase-4 (DPP4) activity inhibition over a 24-hour dose interval was not affected by rifampin.
ND=not determined; QD=once daily; q6h=every 6 hours; q12h=every 12 hours; BID=twice daily; LA=long acting

Table 4: Effect of Saxagliptin on Coadministered Drug Systemic Exposures

<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>Dose of Coadministered Drug*</th>
<th>Dosing of Saxagliptin*</th>
<th>Geometric Mean Ratio (ratio with/without saxagliptin)</th>
<th>AUC†</th>
<th>Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>No Effect = 1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>1000 mg</td>
<td>100 mg</td>
<td>metformin</td>
<td>1.20</td>
<td>1.09</td>
</tr>
<tr>
<td>Glyburide</td>
<td>5 mg</td>
<td>10 mg</td>
<td>glyburide</td>
<td>1.06</td>
<td>1.16</td>
</tr>
<tr>
<td>Pioglitazone‡</td>
<td>45 mg QD for 10 days</td>
<td>10 mg QD for 5 days</td>
<td>pioglitazone hydroxy-pioglitazone</td>
<td>1.08</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.25 mg q6h first day followed by q12h second day followed by QD for 5 days</td>
<td>10 mg QD for 7 days</td>
<td>digoxin</td>
<td>1.06</td>
<td>1.09</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>40 mg QD for 8 days</td>
<td>10 mg QD for 4 days</td>
<td>simvastatin simvastatin acid</td>
<td>1.04</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td>360 mg LA QD for 9 days</td>
<td>10 mg</td>
<td>diltiazem</td>
<td>1.10</td>
<td>1.16</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>200 mg BID for 9 days</td>
<td>100 mg</td>
<td>ketoconazole</td>
<td>0.87</td>
<td>0.84</td>
</tr>
</tbody>
</table>
### Table 4: Effect of Saxagliptin on Coadministered Drug Systemic Exposures

<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>Dose of Coadministered Drug*</th>
<th>Dosing of Saxagliptin*</th>
<th>Geometric Mean Ratio (ratio with/without saxagliptin)</th>
<th>AUC†</th>
<th>C_max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinyl estradiol and Norgestimate</td>
<td>ethinyl estradiol 0.035 mg and norgestimate 0.250 mg for 21 days</td>
<td>5 mg QD for 21 days</td>
<td>ethinyl estradiol norelgestromin norgestrel</td>
<td>1.07</td>
<td>0.98</td>
</tr>
</tbody>
</table>

* Single dose unless otherwise noted.
† AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses
‡ Results include all subjects.
ND=not determined; QD=once daily; q6h=every 6 hours; q12h=every 12 hours; BID=twice daily; LA=long acting

### Table 5: Effect of Coadministered Drug on Plasma Metformin Systemic Exposure

<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>Dose of Coadministered Drug*</th>
<th>Dose of Metformin*</th>
<th>Geometric Mean Ratio (ratio with/without coadministered drug)</th>
<th>AUC†</th>
<th>C_max</th>
</tr>
</thead>
<tbody>
<tr>
<td>No dosing adjustments required for the following:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glyburide</td>
<td>5 mg</td>
<td>850 mg</td>
<td>metformin</td>
<td>0.91†</td>
<td>0.93†</td>
</tr>
<tr>
<td>Furosemide</td>
<td>40 mg</td>
<td>850 mg</td>
<td>metformin</td>
<td>1.09†</td>
<td>1.22†</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>10 mg</td>
<td>850 mg</td>
<td>metformin</td>
<td>1.16</td>
<td>1.21</td>
</tr>
<tr>
<td>Propranolol</td>
<td>40 mg</td>
<td>850 mg</td>
<td>metformin</td>
<td>0.90</td>
<td>0.94</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>400 mg</td>
<td>850 mg</td>
<td>metformin</td>
<td>1.05†</td>
<td>1.07†</td>
</tr>
</tbody>
</table>

Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination: use with caution.
[See Warnings and Precautions (5.10) and Drug Interactions (7.2).]

| Cimetidine | 400 mg | 850 mg | metformin | 1.40 | 1.61 |

* All metformin and coadministered drugs were given as single doses.
† AUC = AUC(INF)
‡ Ratio of arithmetic means
Table 6: Effect of Metformin on Coadministered Drug Systemic Exposure

<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>Dose of Coadministered Drug*</th>
<th>Dose of Metformin*</th>
<th>Geometric Mean Ratio (ratio with/without metformin)</th>
<th>AUC†</th>
<th>C_max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glyburide</td>
<td>5 mg</td>
<td>850 mg</td>
<td>glyburide</td>
<td>0.78‡</td>
<td>0.63‡</td>
</tr>
<tr>
<td>Furosemide</td>
<td>40 mg</td>
<td>850 mg</td>
<td>furosemide</td>
<td>0.87‡</td>
<td>0.69‡</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>10 mg</td>
<td>850 mg</td>
<td>nifedipine</td>
<td>1.10§</td>
<td>1.08</td>
</tr>
<tr>
<td>Propranolol</td>
<td>40 mg</td>
<td>850 mg</td>
<td>propranolol</td>
<td>1.01§</td>
<td>1.02</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>400 mg</td>
<td>850 mg</td>
<td>ibuprofen</td>
<td>0.97¶</td>
<td>1.01¶</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>400 mg</td>
<td>850 mg</td>
<td>cimetidine</td>
<td>0.95§</td>
<td>1.01</td>
</tr>
</tbody>
</table>

* All metformin and coadministered drugs were given as single doses.
‡ AUC = AUC(INF) unless otherwise noted
† Ratio of arithmetic means, p-value of difference <0.05
§ AUC(0-24 hr) reported
¶ Ratio of arithmetic means

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

KOMBIGLYZE XR

No animal studies have been conducted with KOMBIGLYZE XR to evaluate carcinogenesis, mutagenesis, or impairment of fertility. The following data are based on the findings in the studies with saxagliptin and metformin individually.

Saxagliptin

Saxagliptin did not induce tumors in either mice (50, 250, and 600 mg/kg) or rats (25, 75, 150, and 300 mg/kg) at the highest doses evaluated. The highest doses evaluated in mice were equivalent to approximately 870 (males) and 1165 (females) times the human exposure at the MRHD of 5 mg/day. In rats, exposures were approximately 355 (males) and 2217 (females) times the MRHD.
Saxagliptin was not mutagenic or clastogenic with or without metabolic activation in an *in vitro* Ames bacterial assay, an *in vitro* cytogenetics assay in primary human lymphocytes, an *in vivo* oral micronucleus assay in rats, an *in vivo* oral DNA repair study in rats, and an oral *in vivo/in vitro* cytogenetics study in rat peripheral blood lymphocytes. The active metabolite was not mutagenic in an *in vitro* Ames bacterial assay.

In a rat fertility study, males were treated with oral gavage doses for 2 weeks prior to mating, during mating, and up to scheduled termination (approximately 4 weeks total) and females were treated with oral gavage doses for 2 weeks prior to mating through gestation day 7. No adverse effects on fertility were observed at exposures of approximately 603 (males) and 776 (females) times the MRHD. Higher doses that elicited maternal toxicity also increased fetal resorptions (approximately 2069 and 6138 times the MRHD). Additional effects on estrous cycling, fertility, ovulation, and implantation were observed at approximately 6138 times the MRHD.

*Metformin hydrochloride*

Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.

There was no evidence of a mutagenic potential of metformin in the following *in vitro* tests: Ames test (*S. typhimurium*), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the *in vivo* mouse micronucleus test were also negative.

Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.
13.2 Animal Toxicology

*Saxagliptin*

Saxagliptin produced adverse skin changes in the extremities of cynomolgus monkeys (scabs and/or ulceration of tail, digits, scrotum, and/or nose). Skin lesions were reversible at ≥20 times the MRHD but in some cases were irreversible and necrotizing at higher exposures. Adverse skin changes were not observed at exposures similar to (1-3 times) the MRHD of 5 mg. Clinical correlates to skin lesions in monkeys have not been observed in human clinical trials of saxagliptin.

14 CLINICAL STUDIES

There have been no clinical efficacy or safety studies conducted with KOMBIGLYZE XR to characterize its effect on hemoglobin A1c (A1C) reduction. Bioequivalence of KOMBIGLYZE XR with coadministered saxagliptin and metformin hydrochloride extended-release tablets has been demonstrated; however, relative bioavailability studies between KOMBIGLYZE XR and coadministered saxagliptin and metformin hydrochloride immediate-release tablets have not been conducted. The metformin hydrochloride extended-release tablets and metformin hydrochloride immediate-release tablets have a similar extent of absorption (as measured by AUC) while peak plasma levels of extended-release tablets are approximately 20% lower than those of immediate-release tablets at the same dose.

The coadministration of saxagliptin and metformin immediate-release tablets has been studied in adults with type 2 diabetes inadequately controlled on metformin alone and in treatment-naive patients inadequately controlled on diet and exercise alone. In these two trials, treatment with saxagliptin dosed in the morning plus metformin immediate-release tablets at all doses produced clinically relevant and statistically significant improvements in hemoglobin A1c (A1C), fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG) following a standard oral glucose tolerance test (OGTT), compared to control. Reductions in A1C were seen across subgroups including gender, age, race, and baseline BMI.

In these two trials, decrease in body weight in the treatment groups given saxagliptin in combination with metformin immediate-release was similar to that in the groups given metformin immediate-release alone. Saxagliptin plus metformin immediate-release was not associated with significant changes from baseline in fasting serum lipids compared to metformin alone.
The coadministration of saxagliptin and metformin immediate-release tablets has also been evaluated in an active-controlled trial comparing add-on therapy with saxagliptin to glipizide in 858 patients inadequately controlled on metformin alone and in a placebo-controlled trial where a subgroup of 314 patients inadequately controlled on insulin plus metformin received add-on therapy with saxagliptin or placebo.

In a 24-week, double-blind, randomized trial, patients treated with metformin immediate-release 500 mg twice daily for at least 8 weeks were randomized to continued treatment with metformin immediate-release 500 mg twice daily or to metformin extended-release either 1000 mg once daily or 1500 mg once daily. The mean change in A1C from baseline to Week 24 was 0.1% (95% confidence interval 0%, 0.3%) for the metformin immediate-release treatment arm, 0.3% (95% confidence interval 0.1%, 0.4%) for the 1000 mg metformin extended-release treatment arm, and 0.1% (95% confidence interval 0%, 0.3%) for the 1500 mg metformin extended-release treatment arm. Results of this trial suggest that patients receiving metformin immediate-release treatment may be safely switched to metformin extended-release once daily at the same total daily dose, up to 2000 mg once daily. Following a switch from metformin immediate-release to metformin extended-release, glycemic control should be closely monitored and dosage adjustments made accordingly.

**Saxagliptin Morning and Evening Dosing**

A 24-week monotherapy trial was conducted to assess a range of dosing regimens for saxagliptin. Treatment-naive patients with inadequately controlled diabetes (A1C ≥7% to ≤10%) underwent a 2-week, single-blind diet, exercise, and placebo lead-in period. A total of 365 patients were randomized to 2.5 mg every morning, 5 mg every morning, 2.5 mg with possible titration to 5 mg every morning, or 5 mg every evening of saxagliptin, or placebo. Patients who failed to meet specific glycemic goals during the study were treated with metformin rescue therapy added on to placebo or saxagliptin; the number of patients randomized per treatment group ranged from 71 to 74.

Treatment with either saxagliptin 5 mg every morning or 5 mg every evening provided significant improvements in A1C versus placebo (mean placebo-corrected reductions of −0.4% and −0.3%, respectively).
14.1 **Coadministration of Saxagliptin with Metformin Immediate-Release in Treatment-Naive Patients**

A total of 1306 treatment-naive patients with type 2 diabetes mellitus participated in this 24-week, randomized, double-blind, active-controlled trial to evaluate the efficacy and safety of saxagliptin coadministered with metformin immediate-release in patients with inadequate glycemic control (A1C ≥8% to ≤12%) on diet and exercise alone. Patients were required to be treatment-naive to be enrolled in this study.

Patients who met eligibility criteria were enrolled in a single-blind, 1-week, dietary and exercise placebo lead-in period. Patients were randomized to one of four treatment arms: saxagliptin 5 mg + metformin immediate-release 500 mg, saxagliptin 10 mg + metformin immediate-release 500 mg, saxagliptin 10 mg + placebo, or metformin immediate-release 500 mg + placebo (the maximum recommended approved saxagliptin dose is 5 mg daily; the 10 mg daily dose of saxagliptin does not provide greater efficacy than the 5 mg daily dose). Saxagliptin was dosed once daily. In the 3 treatment groups using metformin immediate-release, the metformin dose was up-titrated weekly in 500 mg per day increments, as tolerated, to a maximum of 2000 mg per day based on FPG. Patients who failed to meet specific glycemic goals during this study were treated with pioglitazone rescue as add-on therapy.

Coadministration of saxagliptin 5 mg plus metformin immediate-release provided significant improvements in A1C, FPG, and PPG compared with placebo plus metformin immediate-release (Table 7).

**Table 7: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Coadministration with Metformin Immediate-Release in Treatment-Naive Patients***

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Saxagliptin 5 mg + Metformin N=320</th>
<th>Placebo + Metformin N=328</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin A1C (%) Baseline (mean)</td>
<td>9.4</td>
<td>9.4</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−2.5</td>
<td>−2.0</td>
</tr>
<tr>
<td>Difference from placebo + metformin (adjusted mean†)</td>
<td>−0.5†</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−0.7, −0.4)</td>
<td></td>
</tr>
<tr>
<td>Percent of patients achieving A1C &lt;7%</td>
<td>60%§ (185/307)</td>
<td>41% (129/314)</td>
</tr>
</tbody>
</table>

Reference ID: 3097788
### Table 7: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Coadministration with Metformin Immediate-Release in Treatment-Naive Patients*

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Saxagliptin 5 mg + Metformin</th>
<th>Placebo + Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=320</td>
<td>N=328</td>
</tr>
<tr>
<td><strong>Fasting Plasma Glucose (mg/dL)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>199</td>
<td>199</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−60</td>
<td>−47</td>
</tr>
<tr>
<td>Difference from placebo + metformin (adjusted mean‡)</td>
<td>−13§</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−19, −6)</td>
<td></td>
</tr>
<tr>
<td><strong>2-hour Postprandial Glucose (mg/dL)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>340</td>
<td>355</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−138</td>
<td>−97</td>
</tr>
<tr>
<td>Difference from placebo + metformin (adjusted mean‡)</td>
<td>−41§</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−57, −25)</td>
<td></td>
</tr>
</tbody>
</table>

* Intent-to-treat population using last observation on study or last observation prior to pioglitazone rescue therapy for patients needing rescue.
† Least squares mean adjusted for baseline value.
‡ p-value <0.0001 compared to placebo + metformin
§ p-value <0.05 compared to placebo + metformin

### 14.2 Addition of Saxagliptin to Metformin Immediate-Release

A total of 743 patients with type 2 diabetes participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin in combination with metformin immediate-release in patients with inadequate glycemic control (A1C ≥7% and ≤10%) on metformin alone. To qualify for enrollment, patients were required to be on a stable dose of metformin (1500-2550 mg daily) for at least 8 weeks.

Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received metformin immediate-release at their pre-study dose, up to 2500 mg daily, for the duration of the study. Following the lead-in period, eligible patients were randomized to 2.5 mg, 5 mg, or 10 mg of saxagliptin or placebo in addition to their current dose of open-label metformin immediate-release (the maximum recommended approved saxagliptin dose is 5 mg daily; the 10 mg daily dose of saxagliptin does not provide greater efficacy than the 5 mg daily dose). Patients who failed to meet specific glycemic goals
during the study were treated with pioglitazone rescue therapy, added on to existing study medications. Dose titrations of saxagliptin and metformin immediate-release were not permitted.

Saxagliptin 2.5 mg and 5 mg add-on to metformin immediate-release provided significant improvements in A1C, FPG, and PPG compared with placebo add-on to metformin immediate-release (Table 8). Mean changes from baseline for A1C over time and at endpoint are shown in Figure 1. The proportion of patients who discontinued for lack of glycemic control or who were rescued for meeting prespecified glycemic criteria was 15% in the saxagliptin 2.5 mg add-on to metformin immediate-release group, 13% in the saxagliptin 5 mg add-on to metformin immediate-release group, and 27% in the placebo add-on to metformin immediate-release group.

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Saxagliptin 2.5 mg + Metformin N=192</th>
<th>Saxagliptin 5 mg + Metformin N=191</th>
<th>Placebo + Metformin N=179</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin A1C (%)</td>
<td>N=186</td>
<td>N=186</td>
<td>N=175</td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.1</td>
<td>8.1</td>
<td>8.1</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−0.6</td>
<td>−0.7</td>
<td>+0.1</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean‡)</td>
<td>−0.7‡</td>
<td>−0.8‡</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−0.9, −0.5)</td>
<td>(−1.0, −0.6)</td>
<td></td>
</tr>
<tr>
<td>Percent of patients achieving A1C &lt;7%</td>
<td>37%§ (69/186)</td>
<td>44%§ (81/186)</td>
<td>17% (29/175)</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL) N=188</td>
<td>174</td>
<td>179</td>
<td>175</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−14</td>
<td>−22</td>
<td>+1</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean‡)</td>
<td>−16§</td>
<td>−23§</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−23, −9)</td>
<td>(−30, −16)</td>
<td></td>
</tr>
<tr>
<td>2-hour Postprandial Glucose (mg/dL) N=155</td>
<td>294</td>
<td>296</td>
<td>295</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−62</td>
<td>−58</td>
<td>−18</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean‡)</td>
<td>−44§</td>
<td>−40§</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−60, −27)</td>
<td>(−56, −24)</td>
<td></td>
</tr>
</tbody>
</table>

* Intent-to-treat population using last observation on study or last observation prior to pioglitazone rescue therapy for patients needing rescue.
† Least squares mean adjusted for baseline value.
‡ p-value <0.0001 compared to placebo + metformin
§ p-value <0.05 compared to placebo + metformin

Reference ID: 3097788
14.3 Saxagliptin Add-On Combination Therapy with Metformin Immediate-Release versus Glipizide Add-On Combination Therapy with Metformin Immediate-Release

In this 52-week, active-controlled trial, a total of 858 patients with type 2 diabetes and inadequate glycemic control (A1C >6.5% and ≤10%) on metformin immediate-release alone were randomized to double-blind add-on therapy with saxagliptin or glipizide. Patients were required to be on a stable dose of metformin immediate-release (at least 1500 mg daily) for at least 8 weeks prior to enrollment.

Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received metformin immediate-release (1500-3000 mg based on their prestudy dose). Following the lead-in period, eligible patients were
randomized to 5 mg of saxagliptin or 5 mg of glipizide in addition to their current dose of open-label metformin immediate-release. Patients in the glipizide plus metformin immediate-release group underwent blinded titration of the glipizide dose during the first 18 weeks of the trial up to a maximum glipizide dose of 20 mg per day. Titration was based on a goal FPG ≤ 110 mg/dL or the highest tolerable glipizide dose. Fifty percent (50%) of the glipizide-treated patients were titrated to the 20-mg daily dose; 21% of the glipizide-treated patients had a final daily glipizide dose of 5 mg or less. The mean final daily dose of glipizide was 15 mg.

After 52 weeks of treatment, saxagliptin and glipizide resulted in similar mean reductions from baseline in A1C when added to metformin immediate-release therapy (Table 9). This conclusion may be limited to patients with baseline A1C comparable to those in the trial (91% of patients had baseline A1C < 9%).

From a baseline mean body weight of 89 kg, there was a statistically significant mean reduction of 1.1 kg in patients treated with saxagliptin compared to a mean weight gain of 1.1 kg in patients treated with glipizide (p<0.0001).

**Table 9: Glycemic Parameters at Week 52 in an Active-Controlled Trial of Saxagliptin versus Glipizide in Combination with Metformin Immediate-Release**

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Saxagliptin 5 mg + Metformin N=428</th>
<th>Titrated Glipizide + Metformin N=430</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin A1C (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>7.7</td>
<td>7.6</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−0.6</td>
<td>−0.7</td>
</tr>
<tr>
<td>Difference from glipizide + metformin (adjusted mean†)</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−0.02, 0.2)‡</td>
<td></td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>N=420</td>
<td>N=420</td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>162</td>
<td>161</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−9</td>
<td>−16</td>
</tr>
<tr>
<td>Difference from glipizide + metformin (adjusted mean†)</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(2, 11)§</td>
<td></td>
</tr>
</tbody>
</table>

* Intent-to-treat population using last observation on study.
† Least squares mean adjusted for baseline value.
‡ Saxagliptin + metformin is considered non-inferior to glipizide + metformin because the upper limit of this confidence interval is less than the prespecified non-inferiority margin of 0.35%.
§ Significance not tested.
14.4 Saxagliptin Add-On Combination Therapy with Insulin (with or without Metformin Immediate-Release)

A total of 455 patients with type 2 diabetes participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin in combination with insulin in patients with inadequate glycemic control ($\text{A1C} \geq 7.5\%$ and $\leq 11\%$) on insulin alone ($N=141$) or on insulin in combination with a stable dose of metformin immediate-release ($N=314$). Patients were required to be on a stable dose of insulin ($\geq 30$ units to $\leq 150$ units daily) with $\leq 20\%$ variation in total daily dose for $\geq 8$ weeks prior to screening. Patients entered the trial on intermediate- or long-acting (basal) insulin or premixed insulin. Patients using short-acting insulins were excluded unless the short-acting insulin was administered as part of a premixed insulin.

Patients who met eligibility criteria were enrolled in a single-blind, four-week, dietary and exercise placebo lead-in period during which patients received insulin (and metformin immediate-release if applicable) at their pretrial dose(s). Following the lead-in period, eligible patients were randomized to add-on therapy with either saxagliptin 5 mg or placebo. Doses of the antidiabetic therapies were to remain stable but patients were rescued and allowed to adjust the insulin regimen if specific glycemic goals were not met or if the investigator learned that the patient had self-increased the insulin dose by $>20\%$. Data after rescue were excluded from the primary efficacy analyses.

Add-on therapy with saxagliptin 5 mg provided significant improvements from baseline to Week 24 in A1C and PPG compared with add-on placebo (Table 10). Similar mean reductions in A1C versus placebo were observed for patients using saxagliptin 5 mg add-on to insulin alone and saxagliptin 5 mg add-on to insulin in combination with metformin immediate-release ($-0.4\%$ and $-0.4\%$, respectively). The percentage of patients who discontinued for lack of glycemic control or who were rescued was 23% in the saxagliptin group and 32% in the placebo group.

The mean daily insulin dose at baseline was 53 units in patients treated with saxagliptin 5 mg and 55 units in patients treated with placebo. The mean change from baseline in daily dose of insulin was 2 units for the saxagliptin 5 mg group and 5 units for the placebo group.
Table 10: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin as Add-On Combination Therapy with Insulin*

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Saxagliptin 5 mg + Insulin (+/− Metformin) N=304</th>
<th>Placebo + Insulin (+/− Metformin) N=151</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin A1C (%)</td>
<td>Baseline (mean) N=300</td>
<td>Baseline (mean) N=151</td>
</tr>
<tr>
<td></td>
<td>8.7</td>
<td>8.7</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−0.7</td>
<td>−0.3</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean ‡)</td>
<td>−0.4‡</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−0.6, −0.2)</td>
<td></td>
</tr>
<tr>
<td>Percent of patients achieving A1C &lt;7%</td>
<td>17% (52/300)</td>
<td>7% (10/149)</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>Baseline (mean) N=300</td>
<td>Baseline (mean) N=149</td>
</tr>
<tr>
<td></td>
<td>173</td>
<td>173</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−10</td>
<td>−6</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean ‡)</td>
<td>−4</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−13, 5)</td>
<td></td>
</tr>
<tr>
<td>2-hour Postprandial Glucose (mg/dL)</td>
<td>Baseline (mean) N=262</td>
<td>Baseline (mean) N=129</td>
</tr>
<tr>
<td></td>
<td>251</td>
<td>255</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean†)</td>
<td>−27</td>
<td>−4</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean ‡)</td>
<td>−23§</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>(−37, −9)</td>
<td></td>
</tr>
</tbody>
</table>

* Intent-to-treat population using last observation on study or last observation prior to insulin rescue therapy for patients needing rescue.
† Least squares mean adjusted for baseline value and metformin use at baseline.
‡ p-value <0.0001 compared to placebo + insulin
§ p-value <0.05 compared to placebo + insulin

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release) tablets have markings on both sides and are available in the strengths and packages listed in Table 11.
Table 11: KOMBIGLYZE XR Tablet Presentations

<table>
<thead>
<tr>
<th>Tablet Strength (saxagliptin and metformin HCl extended-release)</th>
<th>Film-Coated Tablet Color/Shape</th>
<th>Tablet Markings</th>
<th>Package Size</th>
<th>NDC Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg/500 mg</td>
<td>light brown to brown, biconvex, capsule-shaped</td>
<td>“5/500” on one side and “4221” on the reverse, in blue ink</td>
<td>Bottles of 30</td>
<td>0003-4221-11</td>
</tr>
<tr>
<td>5 mg/1000 mg</td>
<td>pink, biconvex, capsule-shaped</td>
<td>“5/1000” on one side and “4223” on the reverse, in blue ink</td>
<td>Bottles of 30</td>
<td>0003-4223-11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bottles of 90</td>
<td>0003-4223-21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bottles of 500</td>
<td>0003-4223-31</td>
</tr>
<tr>
<td>2.5 mg/1000 mg</td>
<td>pale yellow to light yellow, biconvex, capsule-shaped</td>
<td>“2.5/1000” on one side and “4222” on the reverse, in blue ink</td>
<td>Bottles of 60</td>
<td>0003-4222-16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bottles of 500</td>
<td>0003-4222-31</td>
</tr>
</tbody>
</table>

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

See FDA-approved Medication Guide.

17.1 Instructions

Patients should be informed of the potential risks and benefits of KOMBIGLYZE XR and of alternative modes of therapy. Patients should also be informed about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and A1C testing, recognition and management of hypoglycemia and hyperglycemia, and assessment of diabetes complications. During periods of stress such as fever, trauma, infection, or surgery, medication requirements may change and patients should be advised to seek medical advice promptly.

The risks of lactic acidosis due to the metformin component, its symptoms and conditions that predispose to its development, as noted in Warnings and Precautions (5.1), should be explained to patients. Patients should be advised to discontinue KOMBIGLYZE XR immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgia, malaise,
unusual somnolence, dizziness, slow or irregular heart beat, sensation of feeling cold (especially in the extremities), or other nonspecific symptoms occur. Gastrointestinal symptoms are common during initiation of metformin treatment and may occur during initiation of KOMBIGLYZE XR therapy; however, patients should consult their physician if they develop unexplained symptoms. Although gastrointestinal symptoms that occur after stabilization are unlikely to be drug related, such an occurrence of symptoms should be evaluated to determine if it may be due to lactic acidosis or other serious disease.

Patients should be counseled against excessive alcohol intake while receiving KOMBIGLYZE XR.

Patients should be informed about the importance of regular testing of renal function and hematological parameters when receiving treatment with KOMBIGLYZE XR.

Patients should be informed that acute pancreatitis has been reported during postmarketing use of saxagliptin. Before initiating KOMBIGLYZE XR, patients should be questioned about other risk factors for pancreatitis, such as a history of pancreatitis, alcoholism, gallstones, or hypertriglycerideridemia. Patients should also be informed that persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting, is the hallmark symptom of acute pancreatitis. Patients should be instructed to promptly discontinue KOMBIGLYZE XR and contact their physician if persistent severe abdominal pain occurs [see Warnings and Precautions (5.2)].

Patients should be informed that the incidence of hypoglycemia may be increased when KOMBIGLYZE XR is added to an insulin secretagogue (e.g., sulfonylurea) or insulin.

Patients should be informed that serious allergic (hypersensitivity) reactions, such as angioedema, anaphylaxis, and exfoliative skin conditions, have been reported during postmarketing use of saxagliptin. If symptoms of these allergic reactions (such as rash, skin flaking or peeling, urticaria, swelling of the skin, or swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing) occur, patients must stop taking KOMBIGLYZE XR and seek medical advice promptly.

Patients should be informed that KOMBIGLYZE XR must be swallowed whole and not crushed or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.
Patients should be informed that if they miss a dose of KOMBIGLYZE XR, they should take the next dose as prescribed, unless otherwise instructed by their healthcare provider. Patients should be instructed not to take an extra dose the next day.

Healthcare providers should instruct their patients to read the Medication Guide before starting KOMBIGLYZE XR therapy and to reread it each time the prescription is renewed. Patients should be instructed to inform their healthcare provider if they develop any unusual symptom or if any existing symptom persists or worsens.

GLUCOPHAGE® is a registered trademark of Merck Santé S.A.S., a subsidiary of Merck KGaA of Darmstadt, Germany, licensed to Bristol-Myers Squibb Company.

ONGLYZA® is a trademark of Bristol-Myers Squibb Company.

Manufactured by:
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

Marketed by:
Bristol-Myers Squibb Company
Princeton, NJ 08543
and
AstraZeneca Pharmaceuticals LP
Wilmington, DE 19850

1281913A1 Rev March 2012